The Department for Health and Social Care has asked NICE to conduct an appraisal of ripretinib within its marketing authorisation for treating advanced gastrointestinal stromal tumours after 3 therapies.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-July 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.